Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Emerging Psoriasis, PsA Drugs and Future Developments in Dermatology, With Linda Stein Gold, MD

 titled ‘Best of the Best at Maui Derm,’ during which its 2 presenters highlighted recent data in the psoriasis treatment space on emerging therapeutic agents.

Linda Stein Gold, MD, director of Dermatology Clinical Research for the Henry Ford Health System, and Jason Hawkes, MD, associate professor of dermatology at the University of California, Davis, presented this talk. Stein Gold, who previously touched on these findings in an 

 interview, was asked in this video about what stood out in the panel discussion about improving early recognition of psoriatic arthritis (PsA).

“When we think about our psoriasis patients, we have to remember that this is a systemic disease, and psoriatic arthritis is one of those manifestations that occurs quite commonly in our psoriasis patients,” Stein Gold explained.

Stein Gold noted during certain times, clinicians should have the potential for PsA development at front of mind. Such patients will specifically have scalp involvement or nail involvement. These patients may require substantial attention in terms of early PsA detection.

Later, Stein Gold was asked about practicing clinicians trying to navigate an increasingly complex therapeutic landscape. Specifically, she was asked which guiding principles she would emphasize when choosing among new and established psoriasis treatments.

“It can be very confusing when we look at our current options and our new options for psoriasis patients, but I think we really owe it to ourselves and to our patients to understand what's going on with each new drug,” Stein Gold explained. “We don't have to know every single drug, but we should get to know drugs in particular categories. Get to know a really good IL-23 drug and IL-17 drug, maybe a TNF-inhibitor, that you're comfortable with. Then let's look at the newer oral agents. Let's look at the TYK2 inhibitors.”

To find out more on the topics covered here, view Stein Gold’s full video above. For more from Maui Derm, view the 

The quotes used in this interview summary were edited for clarity.

Disclosures: Stein Gold has reported serving as an investigator, advisor, or speaker for AbbVie, Amgen, Arctis, Bristol Myers Squibb, Dermavant, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB. AWA has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Arcutis, BMS, Boehringer Ingelheim, Dermavant Sciences, Eli Lilly, Galderma, Incyte, Johnson & Johnson, Leo Pharma, Novartis, Parexel, Pfizer, Regeneron, Sanofi, Takeda, and UCB. RB is an advisory board member, consultant, speaker, investigator for, or received honoraria or grants from AbbVie, Alumis, Amgen, AnaptysBio, Arcutis, BMS/Celgene, Eli Lilly, Johnson & Johnson, LEO Pharma, Organon, Nimbus, Takeda, UCB, VentyxBio, Vyne, Xencor, and Zurabio, and is also an employee and shareholder of Innovaderm Research.

Stein Gold L, Hawkes J. Best of the Best at Maui Derm. Presented at the 2026 Maui Derm Hawaii Conference, January 25-29.

Armstrong AW, Gooderham M, Papp K, et al. Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial. JAMA Dermatol. 2024 Oct 1;160(10):1066-1074. doi: 10.1001/jamadermatol.2024.2701. PMID: 39167366; PMCID: PMC11339701.

Videos

This interview with Stein Gold continues her discussion of new and emerging psoriasis therapies in 2026.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

ASH’s multidisciplinary panel provides a standardized diagnostic pathway emphasizing early laboratory testing and surrogate biopsies.

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

 has published new clinical practice guidelines aimed at improving the early, timely, and accurate diagnosis of light chain (AL) amyloidosis.

The guidelines were published January 28, 2026, in 

 and outline best practices to support clinicians in recognizing and diagnosing AL amyloidosis, a disease frequently missed or diagnosed late due to its heterogeneous presentation.

“These guidelines will be a valuable resource not only for hematologists, but for clinicians across other specialties who care for patients with AL amyloidosis,” said Robert Negrin, MD, ASH President, in a statement. “Because this is a rare and often underrecognized disorder, these recommendations are particularly important for coordinating care and increasing awareness.”

AL amyloidosis is typically a multisystem disease, with amyloid deposits affecting multiple organs. The heart and kidneys are most commonly involved, potentially resulting in cardiomyopathy, renal failure, and pleural or pericardial effusions. Multiorgan dysfunction is strongly associated with poorer outcomes and reduced survival, while 51% to 80% of patients present with cardiac involvement, a major cause of morbidity and mortality in these patients.

The pathogenesis of AL amyloidosis is caused by the misfolding and tissue deposition of monoclonal immunoglobulin light chains produced by abnormal plasma cells. These amyloid deposits, along with circulating free light chains, disrupt normal tissue structure and function, leading to progressive organ damage and increased risk of death, particularly when diagnosis is delayed.

In the past, patients have reported diagnostic delays of >1 year from symptom onset, especially since the presenting symptoms are non-specific, and first-line clinicians may not have disease awareness.

For example, one primary risk factor for AL amyloidosis is increased age, with a median age at diagnosis of approximately 64 years. Since the disease often presents later in life, nonspecific symptoms such as fatigue, weight loss, or reduced appetite are frequently misattributed to aging or more common chronic conditions, contributing to prolonged diagnostic delays.

Despite existing diagnostic tools, the absence of a standardized, evidence-based diagnostic pathway has contributed to prolonged delays and missed diagnoses in AL amyloidosis.

To address this diagnostic gap, the multidisciplinary guideline panel included hematologists, cardiologists, a neurologist, a nephrologist, an internist, a pathologist, and one patient representative. For each recommendation, the Evidence-Based Practice and Impact Center at the University of Kansas Health System conducted systematic evidence reviews and developed GRADE Evidence-to-Decision frameworks to guide recommendations.

The guidelines recommend the use of blood and urine testing, including serum immunofixation, urine immunofixation, and serum free light chain assays, when clinical suspicion for AL amyloidosis exists. To confirm diagnosis, the panel supports the use of surrogate biopsies through combined bone marrow biopsy and fat pad sampling in most cases, while recognizing that target organ biopsies may be appropriate in select clinical scenarios.

“For these patients, time is of the essence,” said Vishal Kukreti, MD, chair of the ASH Guidelines on Diagnosis of Light Chain Amyloidosis and a malignant hematologist at Princess Margaret Cancer Centre, in a statement. “These guidelines will help clinicians across disciplines think of this disease in the right scenarios and provide them with the necessary tools to obtain a clear, accurate diagnosis as quickly as possible.”

Currently, the panel is developing follow-up guidelines focused on the treatment of AL amyloidosis.

ASH publishes clinical practice guidelines on diagnosis of light chain amyloidosis. EurekAlert! Published January 28, 2026. Accessed January 28, 2026. https://www.eurekalert.org/news-releases/1114078

‌McCausland KL, White MK, Guthrie SD, et al. Light Chain (AL) Amyloidosis: The Journey to Diagnosis. 

The Patient - Patient-Centered Outcomes Research

. 2017;11(2):207-216. doi:https://doi.org/10.1007/s40271-017-0273-5

Chatzileontiadou S, Zegkos T, Frouzaki C, et al. Real world data on light chain cardiac amyloidosis: Still a delayed diagnosis. 

. 2022;12. doi:https://doi.org/10.3389/fonc.2022.944503

‌Hester LL, Gifkins DM, Bellew KM, et al. Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019. 

. 2021;107(4):428-435. doi:https://doi.org/10.1111/ejh.13679

Articles

New clinical practice guidelines have been released to enhance the diagnosis of light chain (AL) amyloidosis, a condition often diagnosed late due to its varied presentation. These guidelines aim to assist clinicians across specialties in recognizing and diagnosing this rare disorder, which frequently involves multiple organs, particularly the heart and kidneys. The guidelines recommend specific blood and urine tests and biopsy methods to confirm diagnosis. A multidisciplinary panel developed these recommendations, and follow-up guidelines on treatment are currently in progress.

Hematology

ASH Releases New Clinical Practice Guidelines for Diagnosing AL Amyloidosis

Mazen Noureddin, MD, MHSc, is a professor of medicine and a transplant hepatologist at Houston Methodist and director of the Houston Research Institute.

HCPLive_Horizontal_VideoThumbnails Logan Briggs (2).png

MASH Pipeline Developments and Emerging Therapies to Watch in 2026, With Mazen Noureddin, MD, MHSc

After years of setbacks and uncertainty, the therapeutic landscape for 

metabolic dysfunction–associated steatohepatitis (MASH) and metabolic dysfunction–associated steatotic liver disease (MASLD)

 has entered a decisive new phase. Once characterized by failed trials and a lack of approved therapies, the field has rapidly shifted toward cautious optimism, driven by regulatory clarity, advancing endpoints, and a deepening late-stage pipeline.

“It’s an exciting landscape,” Mazen Noureddin, MD, MHSc, professor of medicine at Houston Methodist Hospital and co-chairman of the Board for Summit and Pinnacle Clinical Research, told 

. “There used to be a pessimistic look on the field from patients and investors. Not so much from researchers, because we started seeing the light at the end of the tunnel and the difficult end points started being formalized back then, and now, in 2026 we're starting with 2 drugs approved, resmetirom and semaglutide.”

He describes 2026 as a pivotal “year of action” for MASH drug development, with 2027 poised to deliver critical outcomes. He notes that the field has already crossed an important threshold, with resmetirom and semaglutide receiving accelerated approvals, while confirmatory outcomes trials continue. Now, the focus is now on demonstrating long-term benefit, particularly the prevention of cirrhosis and hepatic decompensation.

Noureddin additionally highlights several late-stage programs that he believes will shape the next era of care, including the ongoing MAESTRO outcomes trial of resmetirom in patients with cirrhosis. He also points to the momentum around FGF21-based therapies, including efruxifermin, pegozafermin, and efimosfermin, noting multiple high-impact phase 2 publications and active phase 3 programs following major acquisitions by large pharmaceutical companies.

Beyond these programs, Noureddin underscores growing enthusiasm for dual- and triple-agonist approaches, including GLP-1/glucagon combinations now in phase 3 development. He also draws attention to emerging innovation earlier in the pipeline, such as gene therapy approaches targeting FGF21 and novel agents expected to deliver biopsy data in 2026.

Despite this progress, Noureddin also calls attention to persistent unmet needs, including effective therapies for patients with cirrhosis.

“That is doable, but we don't have it handy for the patients, and the clock is ticking in terms of [getting it to them] before they decompensate,” he said. “I would like to see a drug approved as soon as possible for this patient population in particular.”

He also references the development of combination treatment regimens and the urgent push to move away from liver biopsy as a trial requirement as unmet needs he wants to see addressed, but expresses optimism around recent progress in the development of treatments for metabolic dysfunction and alcohol-associated liver disease (MetALD).

Looking ahead, Noureddin says he believes the next 5 years will define the backbone of MASH treatment algorithms, even as progress in decompensated cirrhosis may take longer. Still, he characterizes the current moment as unprecedented and marked by momentum, collaboration, and hope for patients who have long lacked therapeutic options.

Editors’ note: Noureddin reports relevant disclosures with Gilead, GlaxoSmithKline, Madrigal, Novo Nordisk, Takeda, 89BIO, Altimmune, Boehringer Ingelheim, and others.

Brooks A. Resmetirom (Rezdiffra) Receives Historic FDA Approval for Noncirrhotic NASH. HCPLive. March 14, 2024. Accessed January 28, 2026. 

https://www.hcplive.com/view/resmetirom-rezdiffra-receives-historic-fda-approval-for-noncirrhotic-nash

Brooks A. FDA Approves Semaglutide (Wegovy) Injection 2.4 mg for Noncirrhotic MASH. HCPLive. August 15, 2025. Accessed January 28, 2026. 

https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash

Brooks A. Efruxifermin Shows Potential for Fibrosis Reduction in Phase 2b MASH Cirrhosis Trial. HCPLive. May 9, 2025. Accessed January 28, 2026. 

https://www.hcplive.com/view/exfruxifermin-misses-primary-endpoint-phase-2b-compensated-mash-cirrhosis-trial

Brooks A. Pegozafermin Enters Phase 3 Clinical Trial Program for MASH, Fibrosis. HCPLive. March 12, 2024. Accessed January 28, 2026. 

https://www.hcplive.com/view/pegozafermin-enters-phase-3-clinical-trial-program-mash-fibrosis

Noureddin M. Once-Monthly Efimosfermin Alfa Shows Promise for MASH in Phase 2 Study. HCPLive. May 5, 2025. Accessed January 28, 2026. 

https://www.hcplive.com/view/once-monthly-efimosfermin-alfa-shows-promise-mash-in-phase-2-study

Noureddin recaps recent progress in MASH therapeutic development and looks ahead to what 2026 and beyond may offer.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Discussing Icotrokinra for Adolescents, Other Emerging Psoriasis Drugs, With Linda Stein Gold, MD

, held at the Grand Wailea hotel, featured a presentation titled ‘Best of the Best at Maui Derm’ highlighting some of the key recent data on emerging therapeutic agents.

This session was presented by Linda Stein Gold, MD, director of Dermatology Clinical Research for the Henry Ford Health System, and Jason Hawkes, MD, associate professor of dermatology at the University of California, Davis, in Sacramento. Stein Gold sat down with 

 to discuss some of the most notable information highlighted in this talk.

“I think that in 2026, we understand that we have options available for our psoriasis patients to get them under control better than we have in the past, and we have wonderful options in the topical arena. We have these new nonsteroidal options that actually allow us to get patients under control and keep them under control.”

Additionally, Stein Gold highlighted efficacy rates of some of the new nonsteroidals as higher than more traditional nonsteroidal options in the past. Such options may help to simplify the treatment regimens among patients with psoriasis. Stein Gold also highlighted biologic agents getting patients to clear or almost clear and working well for psoriatic arthritis (PsA). Stein Gold was later asked about any specific drugs on the horizon with a significant amount of data behind them.

“We have one oral agent, icotrakinra…and this is a drug that's actually an oral peptide,” Stein Gold said. “It's different from the small molecules in the biologic [realm], and it's been formulated to be better absorbed. This drug actually targets the IL-23 receptor.”

Stein Gold noted icotrokinra was developed to selectively bind the interleukin (IL)-23 receptor and inhibit IL-23–mediated signaling. The medication’s use in patients with moderate-to-severe plaque psoriasis was explored in a variety of phase 3 clinical trials, including LEAD, ADVANCE 1, and ADVANCE 2.2 Stein Gold’s talk at Maui Derm included a discussion of data in adolescent patients specifically.

“We had a recent readout there where the efficacy data is really quite good, long term data does not show any safety signals that we seem to be concerned about,” Stein Gold explained. “We know that when we stop treatment with this drug, we see that we have about 8 - 12 weeks before we lose a PASI 90 or a PASI 75 response.”

For any additional information on these topics, view Stein Gold’s full interview posted above. To find out more from Maui Derm, view the 

The quotes contained in this interview were edited for clarity.

Armstrong A, et al. Comparative analysis of icotrokinra and approved advanced treatments for achievement of completely clear skin in patients with moderate-to-severe psoriasis: A systematic literature review and network meta-analysis. Presented at the 2026 Maui Derm Hawaii Conference, January 25-29. Accessed January 28, 2026.

This interview at the 2026 Maui Derm Hawaii meeting features a discussion of new and emerging therapies in psoriasis, including icotrokinra.

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Liver Lineup: Managing MASLD and MASH Amid Limited Awareness, Overlapping Risk Factors

Liver Lineup: Updates and Unfiltered Insights

, Nancy Reau, MD, and Kimberly Brown, MD, turn their attention to 

metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH)

, conditions that now dominate hepatology clinics but continue to pose major diagnostic and therapeutic challenges. As new drugs enter the clinic and others advance through the pipeline, the hosts explore what meaningful progress looks like in a disease space defined by heterogeneity, comorbidities, and ongoing uncertainty around long-term outcomes.

The conversation opens with reflections on the transition from NAFLD/NASH to MASLD/MASH. Reau and Brown discuss how the updated terminology better captures the metabolic underpinnings of the disease and may help reduce stigma, while acknowledging that changing nomenclature alone does not solve longstanding issues around diagnosis, risk stratification, or patient engagement. They emphasize that many patients with advanced disease are still being identified late in their clinical course.

A central theme of the episode is how clinicians should think about treatment in MASH today. The hosts discuss the significance of having a therapy available for this patient population and what that means for hepatology practice. They underscore the importance of appropriate patient selection, fibrosis assessment, and setting realistic expectations around treatment goals, particularly given the complexity and heterogeneity of the disease.

Reau and Brown also address the role of weight loss and metabolic management in MASLD and MASH. They discuss how improvements in metabolic parameters can translate into liver-related benefits, while noting that sustained lifestyle change remains difficult to achieve and maintain. Pharmacologic approaches that support weight loss are discussed in the context of their broader metabolic effects, rather than as liver-specific therapies.

The episode concludes with a discussion of system-level challenges, including underdiagnosis, inconsistent use of noninvasive testing, and limited awareness outside of hepatology. As MASLD becomes an increasingly common cause of advanced liver disease, the hosts stress the need for better collaboration across specialties and clearer pathways for identifying patients who would benefit from referral and treatment.

Editors’ note: Relevant Disclosures for Reau include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.

Podcasts

Reau and Brown discuss new data on MASH/MASLD, including awareness, referral patterns, discussions around alcohol, and emerging pharmacotherapies.

Liver Lineup: Updates & Unfiltered Insights

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The investigational dual GLP-1/GIP receptor agonist resulted in substantial weight loss without plateau after 48 weeks in patients with obesity.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Genentech Reports Positive Results from Phase 2 Trial of CT-388 in Obesity

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

FDA prioritizes centanafadine's review for ADHD treatment, offering a novel first-in-class NDSRI option for adults, adolescents, and children.

FDA News

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

ADHD

ADHD condition center page is a comprehensive resource for clinical news and insights on ADHD. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for ADHD.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

Sonalika Khachikian, MD, is an endocrinologist at Monument Health.

Earlier diagnosis and more personalized treatment strategies are expected to define the next phase of thyroid eye disease care. 


Video Series

The Future of Thyroid Eye Disease Care: Early Diagnosis and Precision

Paul Nghiem, MD, PhD, leads research at the UW Medicine South Lake Union (SLU) campus, and provides patient care at the Fred Hutch Cancer Center.

This interview segment continues with Paul Nghiem, MD, PhD, highlighting notable insights from his session on cutaneous oncology.

New Therapeutic Options in Cutaneous Oncology for 2026, With Paul Nghiem, MD, PhD

Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.

Cutaneous Oncology Updates for 2026, With Paul Nghiem, MD, PhD

Gianluca Florineth, MSc, from the Translational Research Center, University Hospital of Psychiatry and Psychotherapy at the University of Bern in Switzerland.

Greater exposure to preparation therapy before psychedelic dosing was linked to larger reductions in depressive symptoms, a new study found.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Preparation Before Psychedelics Tied to Better MDD, With Gianluca Florineth, MSc

Ramy Abou-Ghayda, MD, MPH, is the chief of Transformation and Quality, associate professor of urology, and associate program director at University Hospitals, Case Western Reserve University.

Abou-Ghayda breaks down the association between ED and CVD and how this study introduces a new way to address this sensitive topic.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Erectile Dysfunction as a Predictor of Cardiovascular Disease, With Ramy Abou-Ghayda, MD, MPH

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

In a talk given at the Maui Derm 2026 conference, Neal Bhatia, MD, and Ted Rosen, MD, speak on new and upcoming therapies for dermatologic diseases for 2026.

Maui Derm 2026 Presentation Highlights Icotrokinra, Other New Dermatology Drugs

Logan Briggs is a senior urology resident at Mayo Clinic Arizona.

A scoping review of 18 trials finds psychological, nutritional, and exercise support consistently benefits kidney cancer patients.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Timely Psychological, Nutritional, Exercise Referrals May Improve Outcomes for Kidney Cancer Survivors

MannKind Therapeutics has announced new starting dose recommendations for patients with type 1 diabetes switching from injected or insulin pump mealtime therapy.

Latest News

Emerging Psoriasis, PsA Drugs and Future Developments in Dermatology, With Linda Stein Gold, MD

ASH Releases New Clinical Practice Guidelines for Diagnosing AL Amyloidosis

MASH Pipeline Developments and Emerging Therapies to Watch in 2026, With Mazen Noureddin, MD, MHSc

Discussing Icotrokinra for Adolescents, Other Emerging Psoriasis Drugs, With Linda Stein Gold, MD

Liver Lineup: Managing MASLD and MASH Amid Limited Awareness, Overlapping Risk Factors